- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03117192
Zinc Supplementation on Cellular Immunity in Thalassemia Major
연구 개요
상세 설명
Thalassemia refers to a hereditary anaemic condition that occurs due to a single gene disorder resulting in a defect in globin production. Infection is an important cause of morbidity and mortality among thalassemia patients worldwide. Thalassemia patients are more prone to infection. Mechanism of this susceptibility is related to altered immune response compounded by splenectomy procedures common in patients with thalassemia. Zinc on the other hand plays important role in immune responses. This study aims to identify zinc supplementation to cellular immunity of splenectomized patients.
Randomized controlled trial was conducted in post-splenectomy patients aged >12 years. Subjects are randomly assigned to two groups (zinc and placebo). 1.5 mg/kg/day (max 50 mg/day) of Zinc is administered. Anamnesis, physical examination, and laboratory results such as peripheral blood, ferritin, transferrin saturation, serum zinc, immunologic markers for cellular immunity (lymphocyte count, CD4+ and CD8+ T lymphocyte count and functions) are evaluated at the start and end of the 12-week study.
Improvement in immune response is defined as an increase in the T lymphocyte count and CD4+ T lymphocyte count, decrease in CD8+, and increase in the CD4+/CD8+ ratio.12 The mean reference value for CD4+/CD8+ ratio is 1.4 (SD 0.6).15 CD4+ T lymphocyte function refers to its ability to synthesize IL-2 and TNF-α following exposure to 100 µL phytohaemagglutinin with proportions measured using flow cytometry. Meanwhile, CD8+ T lymphocyte function refers to its ability to synthesize IL-2 and TNF-α following exposure to 100 µL phytohaemagglutinin measured using flow cytometry.
The frequency of blood transfusion is calculated from the medical records of the subjects during the past 1 year, which is grouped as follows:
- Seldom receive blood transfusions, if within a time period of one year the subject received blood transfusions of < 1 time.
- Sometimes receive blood transfusions, if within a time period of one year the subject received blood transfusions of 2 - 3 times.
- Often receive blood transfusions, if within a time period of one year the subject received blood transfusions of > 4 times.
Analysis was conducted using Statistical Package for Social Sciences (SPSS) version 20.0. Changes in immunologic parameters between the two groups that are numeric will be analysed using paired t-test for variables with a normal distribution, and Mann-Whitney test for numeric variables with non-normal distributions.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Jakarta
-
Jakarta Pusat, Jakarta, 인도네시아, 10430
- Fakultas Kedokteran Universitas Indonesia
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Thalassemia major patients
- Age > 12 years
- Agreed to participate and signed the informed consent
- No other comorbidity beside thalassemia
Exclusion Criteria:
- HIV positive patients
- Those in steroid medication
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Zinc sulfate
Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
|
Zinc supplementation in syrup form
|
|
위약 비교기: Sucrose syrup
Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
|
Sucrose as placebo, with same taste and consistency as zinc
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Patient's T-lymphocyte count
기간: 12 weeks
|
Measurement of patients CD4+ and CD8+ T-lymphocyte count in uL
|
12 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Teny T Sari, M.D., PhD, Faculty of Medicine University of Indonesia
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
지중해빈혈에 대한 임상 시험
-
Tanta University알려지지 않은Beta Thalassemia Major가있는 Nigella Sativa이집트
Zinc Sulfate에 대한 임상 시험
-
Pfizer아직 모집하지 않음
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University완전한
-
Valenta Pharm JSC모병
-
Pfizer완전한편두통이탈리아, 스페인, 벨기에, 미국, 핀란드, 폴란드, 캐나다, 오스트리아, 영국, 스웨덴, 호주, 덴마크, 독일, 멕시코